Marvel Biosciences Corp. is a Canada-based pre-clinical stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a novel fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.
Metrics to compare | MRVL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRVLPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.7x | −0.5x | |
PEG Ratio | 0.00 | 0.04 | 0.00 | |
Price/Book | 0.0x | 2.1x | 2.6x | |
Price / LTM Sales | 0.0x | 2.3x | 3.3x | |
Upside (Analyst Target) | 0.0% | 254.3% | 43.5% | |
Fair Value Upside | Unlock | 2.2% | 6.9% | Unlock |